Logo of heartHeartVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Heart. Dec 2005; 91(Suppl 5): v1–v52.
PMCID: PMC1876394

JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice

Full Text

The Full Text of this article is available as a PDF (878K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Primatesta P, Brookes M, Poulter NR. Improved hypertension management and control: results from the health survey for England 1998. Hypertension. 2001 Oct;38(4):827–832. [PubMed]
  • Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation. 1991 Jan;83(1):356–362. [PubMed]
  • Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, McG Thom S. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens. 2004 Mar;18(3):139–185. [PubMed]
  • Smith Sidney C, Jr, Jackson Rod, Pearson Thomas A, Fuster Valentin, Yusuf Salim, Faergeman Ole, Wood David A, Alderman Michael, Horgan John, Home Philip, et al. Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Forum. Circulation. 2004 Jun 29;109(25):3112–3121. [PubMed]
  • Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991 Jan;121(1 Pt 2):293–298. [PubMed]
  • Durrington PN, Prais H, Bhatnagar D, France M, Crowley V, Khan J, Morgan J. Indications for cholesterol-lowering medication: comparison of risk-assessment methods. Lancet. 1999 Jan 23;353(9149):278–281. [PubMed]
  • Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetière P, Jousilahti P, Keil U, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003 Jun;24(11):987–1003. [PubMed]
  • Brindle Peter, Emberson Jonathan, Lampe Fiona, Walker Mary, Whincup Peter, Fahey Tom, Ebrahim Shah. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ. 2003 Nov 29;327(7426):1267–1267. [PMC free article] [PubMed]
  • Stevens RJ, Kothari V, Adler AI, Stratton IM. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 2001 Dec;101(6):671–679. [PubMed]
  • Song SH, Brown PM. Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabet Med. 2004 Mar;21(3):238–245. [PubMed]
  • Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, McG Thom S. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens. 2004 Mar;18(3):139–185. [PubMed]
  • Doll Richard, Peto Richard, Boreham Jillian, Sutherland Isabelle. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ. 2004 Jun 26;328(7455):1519–1519. [PMC free article] [PubMed]
  • Bartecchi CE, MacKenzie TD, Schrier RW. The human costs of tobacco use (1) N Engl J Med. 1994 Mar 31;330(13):907–912. [PubMed]
  • MacKenzie TD, Bartecchi CE, Schrier RW. The human costs of tobacco use (2) N Engl J Med. 1994 Apr 7;330(14):975–980. [PubMed]
  • Wilhelmsen L. Coronary heart disease: epidemiology of smoking and intervention studies of smoking. Am Heart J. 1988 Jan;115(1 Pt 2):242–249. [PubMed]
  • Manson JE, Tosteson H, Ridker PM, Satterfield S, Hebert P, O'Connor GT, Buring JE, Hennekens CH. The primary prevention of myocardial infarction. N Engl J Med. 1992 May 21;326(21):1406–1416. [PubMed]
  • Howard G, Wagenknecht LE, Burke GL, Diez-Roux A, Evans GW, McGovern P, Nieto FJ, Tell GS. Cigarette smoking and progression of atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study. JAMA. 1998 Jan 14;279(2):119–124. [PubMed]
  • Law MR, Morris JK, Wald NJ. Environmental tobacco smoke exposure and ischaemic heart disease: an evaluation of the evidence. BMJ. 1997 Oct 18;315(7114):973–980. [PMC free article] [PubMed]
  • Wilson K, Gibson N, Willan A, Cook D. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med. 2000 Apr 10;160(7):939–944. [PubMed]
  • Kawachi I, Colditz GA, Stampfer MJ, Willett WC, Manson JE, Rosner B, Hunter DJ, Hennekens CH, Speizer FE. Smoking cessation in relation to total mortality rates in women. A prospective cohort study. Ann Intern Med. 1993 Nov 15;119(10):992–1000. [PubMed]
  • Dobson AJ, Alexander HM, Heller RF, Lloyd DM. How soon after quitting smoking does risk of heart attack decline? J Clin Epidemiol. 1991;44(11):1247–1253. [PubMed]
  • Kawachi I, Colditz GA, Stampfer MJ, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Smoking cessation and time course of decreased risks of coronary heart disease in middle-aged women. Arch Intern Med. 1994 Jan 24;154(2):169–175. [PubMed]
  • Rosenberg SA. Combined modality therapy of cancer. What is it and when does it work? N Engl J Med. 1985 Jun 6;312(23):1512–1514. [PubMed]
  • Raw M, McNeill A, West R. Smoking cessation: evidence based recommendations for the healthcare system. BMJ. 1999 Jan 16;318(7177):182–185. [PMC free article] [PubMed]
  • Balfour D, Benowitz N, Fagerström K, Kunze M, Keil U. Diagnosis and treatment of nicotine dependence with emphasis on nicotine replacement therapy. A status report. Eur Heart J. 2000 Mar;21(6):438–445. [PubMed]
  • Clarke R, Frost C, Collins R, Appleby P, Peto R. Dietary lipids and blood cholesterol: quantitative meta-analysis of metabolic ward studies. BMJ. 1997 Jan 11;314(7074):112–117. [PMC free article] [PubMed]
  • Hooper L, Summerbell CD, Higgins JP, Thompson RL, Capps NE, Smith GD, Riemersma RA, Ebrahim S. Dietary fat intake and prevention of cardiovascular disease: systematic review. BMJ. 2001 Mar 31;322(7289):757–763. [PMC free article] [PubMed]
  • Hu FB, Stampfer MJ, Manson JE, Rimm E, Colditz GA, Rosner BA, Hennekens CH, Willett WC. Dietary fat intake and the risk of coronary heart disease in women. N Engl J Med. 1997 Nov 20;337(21):1491–1499. [PubMed]
  • Ascherio A, Rimm EB, Giovannucci EL, Spiegelman D, Stampfer M, Willett WC. Dietary fat and risk of coronary heart disease in men: cohort follow up study in the United States. BMJ. 1996 Jul 13;313(7049):84–90. [PMC free article] [PubMed]
  • Dolecek TA. Epidemiological evidence of relationships between dietary polyunsaturated fatty acids and mortality in the multiple risk factor intervention trial. Proc Soc Exp Biol Med. 1992 Jun;200(2):177–182. [PubMed]
  • Hu FB, Stampfer MJ, Manson JE, Rimm EB, Wolk A, Colditz GA, Hennekens CH, Willett WC. Dietary intake of alpha-linolenic acid and risk of fatal ischemic heart disease among women. Am J Clin Nutr. 1999 May;69(5):890–897. [PubMed]
  • de Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I, Guidollet J, Touboul P, Delaye J. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet. 1994 Jun 11;343(8911):1454–1459. [PubMed]
  • Law M. Plant sterol and stanol margarines and health. BMJ. 2000 Mar 25;320(7238):861–864. [PMC free article] [PubMed]
  • Albert Christine M, Campos Hannia, Stampfer Meir J, Ridker Paul M, Manson JoAnn E, Willett Walter C, Ma Jing. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med. 2002 Apr 11;346(15):1113–1118. [PubMed]
  • Hu Frank B, Bronner Leslie, Willett Walter C, Stampfer Meir J, Rexrode Kathryn M, Albert Christine M, Hunter David, Manson JoAnn E. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA. 2002 Apr 10;287(14):1815–1821. [PubMed]
  • Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet. 1989 Sep 30;2(8666):757–761. [PubMed]
  • Marchioli Roberto, Barzi Federica, Bomba Elena, Chieffo Carmine, Di Gregorio Domenico, Di Mascio Rocco, Franzosi Maria Grazia, Geraci Enrico, Levantesi Giacomo, Maggioni Aldo Pietro, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002 Apr 23;105(16):1897–1903. [PubMed]
  • Bucher Heiner C, Hengstler Peter, Schindler Christian, Meier Gabriela. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med. 2002 Mar;112(4):298–304. [PubMed]
  • Tang JL, Armitage JM, Lancaster T, Silagy CA, Fowler GH, Neil HA. Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects. BMJ. 1998 Apr 18;316(7139):1213–1220. [PMC free article] [PubMed]
  • Katan MB, Beynen AC. Characteristics of human hypo- and hyperresponders to dietary cholesterol. Am J Epidemiol. 1987 Mar;125(3):387–399. [PubMed]
  • Law MR, Morris JK. By how much does fruit and vegetable consumption reduce the risk of ischaemic heart disease? Eur J Clin Nutr. 1998 Aug;52(8):549–556. [PubMed]
  • Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER, 3rd, Simons-Morton DG, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001 Jan 4;344(1):3–10. [PubMed]
  • Hooper Lee, Bartlett Christopher, Davey Smith George, Ebrahim Shah. Systematic review of long term effects of advice to reduce dietary salt in adults. BMJ. 2002 Sep 21;325(7365):628–628. [PMC free article] [PubMed]
  • Vollmer WM, Sacks FM, Ard J, Appel LJ, Bray GA, Simons-Morton DG, Conlin PR, Svetkey LP, Erlinger TP, Moore TJ, et al. Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. Ann Intern Med. 2001 Dec 18;135(12):1019–1028. [PubMed]
  • Hooper L, Ness AR, Smith GD. Antioxidant strategy for cardiovascular diseases. Lancet. 2001 May 26;357(9269):1705–1706. [PubMed]
  • Rapola JM, Virtamo J, Ripatti S, Huttunen JK, Albanes D, Taylor PR, Heinonen OP. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet. 1997 Jun 14;349(9067):1715–1720. [PubMed]
  • Corrao G, Rubbiati L, Bagnardi V, Zambon A, Poikolainen K. Alcohol and coronary heart disease: a meta-analysis. Addiction. 2000 Oct;95(10):1505–1523. [PubMed]
  • Power C, Rodgers B, Hope S. U-shaped relation for alcohol consumption and health in early adulthood and implications for mortality. Lancet. 1998 Sep 12;352(9131):877–877. [PubMed]
  • Rimm EB, Klatsky A, Grobbee D, Stampfer MJ. Review of moderate alcohol consumption and reduced risk of coronary heart disease: is the effect due to beer, wine, or spirits. BMJ. 1996 Mar 23;312(7033):731–736. [PMC free article] [PubMed]
  • Britton A, McKee M. The relation between alcohol and cardiovascular disease in Eastern Europe: explaining the paradox. J Epidemiol Community Health. 2000 May;54(5):328–332. [PMC free article] [PubMed]
  • Mazzaglia G, Britton AR, Altmann DR, Chenet L. Exploring the relationship between alcohol consumption and non-fatal or fatal stroke: a systematic review. Addiction. 2001 Dec;96(12):1743–1756. [PubMed]
  • Gill JS, Shipley MJ, Tsementzis SA, Hornby RS, Gill SK, Hitchcock ER, Beevers DG. Alcohol consumption--a risk factor for hemorrhagic and non-hemorrhagic stroke. Am J Med. 1991 Apr;90(4):489–497. [PubMed]
  • Klatsky AL. Alcohol, coronary disease, and hypertension. Annu Rev Med. 1996;47:149–160. [PubMed]
  • Kauhanen J, Kaplan GA, Goldberg DE, Salonen JT. Beer binging and mortality: results from the Kuopio ischaemic heart disease risk factor study, a prospective population based study. BMJ. 1997 Oct 4;315(7112):846–851. [PMC free article] [PubMed]
  • Berlin JA, Colditz GA. A meta-analysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol. 1990 Oct;132(4):612–628. [PubMed]
  • Rosengren A, Wilhelmsen L. Physical activity protects against coronary death and deaths from all causes in middle-aged men. Evidence from a 20-year follow-up of the primary prevention study in Göteborg. Ann Epidemiol. 1997 Jan;7(1):69–75. [PubMed]
  • Folsom AR, Arnett DK, Hutchinson RG, Liao F, Clegg LX, Cooper LS. Physical activity and incidence of coronary heart disease in middle-aged women and men. Med Sci Sports Exerc. 1997 Jul;29(7):901–909. [PubMed]
  • Wannamethee SG, Shaper AG, Walker M. Changes in physical activity, mortality, and incidence of coronary heart disease in older men. Lancet. 1998 May 30;351(9116):1603–1608. [PubMed]
  • Goldbourt U. Physical activity, long-term CHD mortality and longevity: a review of studies over the last 30 years. World Rev Nutr Diet. 1997;82:229–239. [PubMed]
  • Leon AS, Myers MJ, Connett J. Leisure time physical activity and the 16-year risks of mortality from coronary heart disease and all-causes in the Multiple Risk Factor Intervention Trial (MRFIT). Int J Sports Med. 1997 Jul;18 (Suppl 3):S208–S215. [PubMed]
  • Pate RR, Pratt M, Blair SN, Haskell WL, Macera CA, Bouchard C, Buchner D, Ettinger W, Heath GW, King AC, et al. Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA. 1995 Feb 1;273(5):402–407. [PubMed]
  • Thompson Paul D, Buchner David, Pina Ileana L, Balady Gary J, Williams Mark A, Marcus Bess H, Berra Kathy, Blair Steven N, Costa Fernando, Franklin Barry, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation. 2003 Jun 24;107(24):3109–3116. [PubMed]
  • Williams PT. Physical fitness and activity as separate heart disease risk factors: a meta-analysis. Med Sci Sports Exerc. 2001 May;33(5):754–761. [PMC free article] [PubMed]
  • Fagard Robert H. Physical exercise and coronary artery disease. Acta Cardiol. 2002 Apr;57(2):91–100. [PubMed]
  • Braith RW, Pollock ML, Lowenthal DT, Graves JE, Limacher MC. Moderate- and high-intensity exercise lowers blood pressure in normotensive subjects 60 to 79 years of age. Am J Cardiol. 1994 Jun 1;73(15):1124–1128. [PubMed]
  • Kokkinos PF, Narayan P, Colleran JA, Pittaras A, Notargiacomo A, Reda D, Papademetriou V. Effects of regular exercise on blood pressure and left ventricular hypertrophy in African-American men with severe hypertension. N Engl J Med. 1995 Nov 30;333(22):1462–1467. [PubMed]
  • Arroll B, Beaglehole R. Exercise for hypertension. Lancet. 1993 May 15;341(8855):1248–1249. [PubMed]
  • Taylor Rod S, Brown Allan, Ebrahim Shah, Jolliffe Judith, Noorani Hussein, Rees Karen, Skidmore Becky, Stone James A, Thompson David R, Oldridge Neil. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med. 2004 May 15;116(10):682–692. [PubMed]
  • Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW., Jr Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999 Oct 7;341(15):1097–1105. [PubMed]
  • Jousilahti P, Tuomilehto J, Vartiainen E, Pekkanen J, Puska P. Body weight, cardiovascular risk factors, and coronary mortality. 15-year follow-up of middle-aged men and women in eastern Finland. Circulation. 1996 Apr 1;93(7):1372–1379. [PubMed]
  • Rexrode KM, Hennekens CH, Willett WC, Colditz GA, Stampfer MJ, Rich-Edwards JW, Speizer FE, Manson JE. A prospective study of body mass index, weight change, and risk of stroke in women. JAMA. 1997 May 21;277(19):1539–1545. [PubMed]
  • Abbott RD, Behrens GR, Sharp DS, Rodriguez BL, Burchfiel CM, Ross GW, Yano K, Curb JD. Body mass index and thromboembolic stroke in nonsmoking men in older middle age. The Honolulu Heart Program. Stroke. 1994 Dec;25(12):2370–2376. [PubMed]
  • Molarius A, Seidell JC. Selection of anthropometric indicators for classification of abdominal fatness--a critical review. Int J Obes Relat Metab Disord. 1998 Aug;22(8):719–727. [PubMed]
  • Després JP. Health consequences of visceral obesity. Ann Med. 2001 Nov;33(8):534–541. [PubMed]
  • Grundy SM. Metabolic complications of obesity. Endocrine. 2000 Oct;13(2):155–165. [PubMed]
  • Neter Judith E, Stam Bianca E, Kok Frans J, Grobbee Diederick E, Geleijnse Johanna M. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003 Nov;42(5):878–884. [PubMed]
  • Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr. 1992 Aug;56(2):320–328. [PubMed]
  • Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res. 2001 Nov;9 (Suppl 4):326S–334S. [PubMed]
  • O'Meara S, Glenny AM, Wilson C, Melville A, Sheldon TA. Effective management of obesity. Qual Health Care. 1997 Sep;6(3):170–175. [PMC free article] [PubMed]
  • Padwal R, Li SK, Lau DCW. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord. 2003 Dec;27(12):1437–1446. [PubMed]
  • Kim Su Hyun, Lee Young Mee, Jee Sun Ha, Nam Chung Mo. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res. 2003 Sep;11(9):1116–1123. [PubMed]
  • Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, Levy D. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001 Nov 1;345(18):1291–1297. [PubMed]
  • MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990 Mar 31;335(8692):765–774. [PubMed]
  • Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996 May 22;275(20):1571–1576. [PubMed]
  • Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, Persson G, Odén A, Svanborg A. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996 Apr 27;347(9009):1141–1145. [PubMed]
  • Williams Bryan. Protection against stroke and dementia: an update on the latest clinical trial evidence. Curr Hypertens Rep. 2004 Aug;6(4):307–313. [PubMed]
  • Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. JAMA. 1992 Dec 2;268(21):3085–3091. [PubMed]
  • Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, McG Thom S. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens. 2004 Mar;18(3):139–185. [PubMed]
  • Williams Bryan, Poulter Neil R, Brown Morris J, Davis Mark, McInnes Gordon T, Potter John F, Sever Peter S, Thom Simon McG. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ. 2004 Mar 13;328(7440):634–640. [PMC free article] [PubMed]
  • Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997 Sep 13;350(9080):757–764. [PubMed]
  • Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Scherstén B, Wester PO, Hedner T, de Faire U. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999 Nov 20;354(9192):1751–1756. [PubMed]
  • Wing Lindon M H, Reid Christopher M, Ryan Philip, Beilin Lawrence J, Brown Mark A, Jennings Garry L R, Johnston Colin I, McNeil John J, Macdonald Graham J, Marley John E, et al. A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003 Feb 13;348(7):583–592. [PubMed]
  • Lithell Hans, Hansson Lennart, Skoog Ingmar, Elmfeldt Dag, Hofman Albert, Olofsson Bertil, Trenkwalder Peter, Zanchetti Alberto. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003 May;21(5):875–886. [PubMed]
  • Forette F, Seux ML, Staessen JA, Thijs L, Birkenhäger WH, Babarskiene MR, Babeanu S, Bossini A, Gil-Extremera B, Girerd X, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998 Oct 24;352(9137):1347–1351. [PubMed]
  • Gueyffier F, Bulpitt C, Boissel JP, Schron E, Ekbom T, Fagard R, Casiglia E, Kerlikowske K, Coope J. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group. Lancet. 1999 Mar 6;353(9155):793–796. [PubMed]
  • Bulpitt C, Fletcher A, Beckett N, Coope J, Gil-Extremera B, Forette F, Nachev C, Potter J, Sever P, Staessen J, et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs Aging. 2001;18(3):151–164. [PubMed]
  • Staessen Jan A, Wang Ji-Guang, Thijs Lutgarde. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens. 2003 Jun;21(6):1055–1076. [PubMed]
  • Psaty Bruce M, Lumley Thomas, Furberg Curt D, Schellenbaum Gina, Pahor Marco, Alderman Michael H, Weiss Noel S. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003 May 21;289(19):2534–2544. [PubMed]
  • Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000 Jul 29;356(9227):366–372. [PubMed]
  • Williams Bryan. Recent hypertension trials: implications and controversies. J Am Coll Cardiol. 2005 Mar 15;45(6):813–827. [PubMed]
  • Verma Subodh, Strauss Marty. Angiotensin receptor blockers and myocardial infarction. BMJ. 2004 Nov 27;329(7477):1248–1249. [PMC free article] [PubMed]
  • Dahlöf Björn, Devereux Richard B, Kjeldsen Sverre E, Julius Stevo, Beevers Gareth, de Faire Ulf, Fyhrquist Frej, Ibsen Hans, Kristiansson Krister, Lederballe-Pedersen Ole, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002 Mar 23;359(9311):995–1003. [PubMed]
  • Julius Stevo, Kjeldsen Sverre E, Weber Michael, Brunner Hans R, Ekman Steffan, Hansson Lennart, Hua Tsushung, Laragh John, McInnes Gordon T, Mitchell Lada, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004 Jun 19;363(9426):2022–2031. [PubMed]
  • O'Brien Eoin, Asmar Roland, Beilin Lawrie, Imai Yutaka, Mallion Jean-Michel, Mancia Giuseppe, Mengden Thomas, Myers Martin, Padfield Paul, Palatini Paolo, et al. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens. 2003 May;21(5):821–848. [PubMed]
  • Stergiou George, Mengden Thomas, Padfield Paul L, Parati Gianfranco, O'Brien Eoin. Self monitoring of blood pressure at home. BMJ. 2004 Oct 16;329(7471):870–871. [PMC free article] [PubMed]
  • Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, Lanke J, de Faire U, Dahlöf B, Karlberg BE. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000 Jul 29;356(9227):359–365. [PubMed]
  • Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmäki K, Dahlöf B, de Faire U, Mörlin C, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999 Feb 20;353(9153):611–616. [PubMed]
  • Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001 Sep 20;345(12):870–878. [PubMed]
  • Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001 Sep 20;345(12):861–869. [PubMed]
  • Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 Sep 20;345(12):851–860. [PubMed]
  • Pepine Carl J, Handberg Eileen M, Cooper-DeHoff Rhonda M, Marks Ronald G, Kowey Peter, Messerli Franz H, Mancia Giuseppe, Cangiano José L, Garcia-Barreto David, Keltai Matyas, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003 Dec 3;290(21):2805–2816. [PubMed]
  • Black Henry R, Elliott William J, Grandits Gregory, Grambsch Patricia, Lucente Tracy, White William B, Neaton James D, Grimm Richard H, Jr, Hansson Lennart, Lacourciere Yves, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003 Apr 23;289(16):2073–2082. [PubMed]
  • Wright Jackson T, Jr, Bakris George, Greene Tom, Agodoa Larry Y, Appel Lawrence J, Charleston Jeanne, Cheek DeAnna, Douglas-Baltimore Janice G, Gassman Jennifer, Glassock Richard, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002 Nov 20;288(19):2421–2431. [PubMed]
  • Primatesta P, Brookes M, Poulter NR. Improved hypertension management and control: results from the health survey for England 1998. Hypertension. 2001 Oct;38(4):827–832. [PubMed]
  • Brown MJ, Cruickshank JK, Dominiczak AF, MacGregor GA, Poulter NR, Russell GI, Thom S, Williams B. Better blood pressure control: how to combine drugs. J Hum Hypertens. 2003 Feb;17(2):81–86. [PubMed]
  • Dahlöf Björn, Sever Peter S, Poulter Neil R, Wedel Hans, Beevers D Gareth, Caulfield Mark, Collins Rory, Kjeldsen Sverre E, Kristinsson Arni, McInnes Gordon T, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005 Sep 10;366(9489):895–906. [PubMed]
  • Nissen Steven E, Tuzcu E Murat, Libby Peter, Thompson Paul D, Ghali Magdi, Garza Dahlia, Berman Lance, Shi Harry, Buebendorf Ethel, Topol Eric J, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004 Nov 10;292(18):2217–2225. [PubMed]
  • Lawlor Debbie A, Smith George Davey, Leon David A, Sterne Jonathan A C, Ebrahim Shah. Secular trends in mortality by stroke subtype in the 20th century: a retrospective analysis. Lancet. 2002 Dec 7;360(9348):1818–1823. [PubMed]
  • Wolfe CD, Tilling K, Beech R, Rudd AG. Variations in case fatality and dependency from stroke in western and central Europe. The European BIOMED Study of Stroke Care Group. Stroke. 1999 Feb;30(2):350–356. [PubMed]
  • Dennis MS, Burn JP, Sandercock PA, Bamford JM, Wade DT, Warlow CP. Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke. 1993 Jun;24(6):796–800. [PubMed]
  • Gariballa SE, Robinson TG, Parker SG, Castleden CM. A prospective study of primary and secondary risk factor management in stroke patients. J R Coll Physicians Lond. 1995 Nov-Dec;29(6):485–487. [PubMed]
  • Harper G, Castleden CM, Potter JF. Factors affecting changes in blood pressure after acute stroke. Stroke. 1994 Sep;25(9):1726–1729. [PubMed]
  • Robinson Thompson G, Potter John F. Blood pressure in acute stroke. Age Ageing. 2004 Jan;33(1):6–12. [PubMed]
  • Britton M, Carlsson A. Very high blood pressure in acute stroke. J Intern Med. 1990 Dec;228(6):611–615. [PubMed]
  • Carlberg B, Asplund K, Hägg E. The prognostic value of admission blood pressure in patients with acute stroke. Stroke. 1993 Sep;24(9):1372–1375. [PubMed]
  • Schrader Joachim, Lüders Stephan, Kulschewski Anke, Berger Jürgen, Zidek Walter, Treib Johannes, Einhäupl Karl, Diener Hans Christoph, Dominiak Peter. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke. 2003 Jul;34(7):1699–1703. [PubMed]
  • Adams Harold P, Jr, Adams Robert J, Brott Thomas, del Zoppo Gregory J, Furlan Anthony, Goldstein Larry B, Grubb Robert L, Higashida Randall, Kidwell Chelsea, Kwiatkowski Thomas G, et al. Guidelines for the early management of patients with ischemic stroke: A scientific statement from the Stroke Council of the American Stroke Association. Stroke. 2003 Apr;34(4):1056–1083. [PubMed]
  • Carlsson A, Britton M. Blood pressure after stroke. A one-year follow-up study. Stroke. 1993 Feb;24(2):195–199. [PubMed]
  • Lawes Carlene M M, Bennett Derrick A, Feigin Valery L, Rodgers Anthony. Blood pressure and stroke: an overview of published reviews. Stroke. 2004 Mar;35(3):776–785. [PubMed]
  • Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R, Shih J, Stamler J, Wentworth D. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med. 1992 Jul;152(7):1490–1500. [PubMed]
  • Smith GD, Shipley MJ, Marmot MG, Rose G. Plasma cholesterol concentration and mortality. The Whitehall Study. JAMA. 1992 Jan 1;267(1):70–76. [PubMed]
  • Clarke R, Lewington S, Youngman L, Sherliker P, Peto R, Collins R. Underestimation of the importance of blood pressure and cholesterol for coronary heart disease mortality in old age. Eur Heart J. 2002 Feb;23(4):286–293. [PubMed]
  • Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med. 1992 Jan;152(1):56–64. [PubMed]
  • Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994 Feb 5;308(6925):367–372. [PMC free article] [PubMed]
  • Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ. 1990 Aug 11;301(6747):309–314. [PMC free article] [PubMed]
  • Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation. 1990 Dec;82(6):1916–1924. [PubMed]
  • Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers TC. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. JAMA. 1992 Jul 8;268(2):240–248. [PubMed]
  • Smith GD, Song F, Sheldon TA. Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ. 1993 May 22;306(6889):1367–1373. [PMC free article] [PubMed]
  • Superko HR, Krauss RM. Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management. Circulation. 1994 Aug;90(2):1056–1069. [PubMed]
  • Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit. A new look at old data. Circulation. 1995 Apr 15;91(8):2274–2282. [PubMed]
  • Bucher HC, Griffith LE, Guyatt GH. Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol. 1999 Feb;19(2):187–195. [PubMed]
  • Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003 Jun 28;326(7404):1423–1423. [PMC free article] [PubMed]
  • Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, Wilhelmsen L, Haghfelt T, Thorgeirsson G, Pyörälä K, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) Circulation. 1998 Apr 21;97(15):1453–1460. [PubMed]
  • Simes R John, Marschner Ian C, Hunt David, Colquhoun David, Sullivan David, Stewart Ralph A H, Hague Wendy, Keech Anthony, Thompson Peter, White Harvey, et al. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation. 2002 Mar 12;105(10):1162–1169. [PubMed]
  • Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA. 1997 Jul 23;278(4):313–321. [PubMed]
  • Crouse JR, 3rd, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med. 1997 Jun 23;157(12):1305–1310. [PubMed]
  • Bucher HC, Griffith LE, Guyatt GH. Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials. Ann Intern Med. 1998 Jan 15;128(2):89–95. [PubMed]
  • LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999 Dec 22;282(24):2340–2346. [PubMed]
  • Lewis SJ, Moye LA, Sacks FM, Johnstone DE, Timmis G, Mitchell J, Limacher M, Kell S, Glasser SP, Grant J, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med. 1998 Nov 1;129(9):681–689. [PubMed]
  • Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995 Nov 16;333(20):1301–1307. [PubMed]
  • Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM., Jr Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998 May 27;279(20):1615–1622. [PubMed]
  • Sever Peter S, Dahlöf Björn, Poulter Neil R, Wedel Hans, Beevers Gareth, Caulfield Mark, Collins Rory, Kjeldsen Sverre E, Kristinsson Arni, McInnes Gordon T, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003 Apr 5;361(9364):1149–1158. [PubMed]
  • Colhoun Helen M, Betteridge D John, Durrington Paul N, Hitman Graham A, Neil H Andrew W, Livingstone Shona J, Thomason Margaret J, Mackness Michael I, Charlton-Menys Valentine, Fuller John H, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004 Aug 21;364(9435):685–696. [PubMed]
  • Waters David D, Guyton John R, Herrington David M, McGowan Mary P, Wenger Nanette K, Shear Charles. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol. 2004 Jan 15;93(2):154–158. [PubMed]
  • Pedersen Terje R, Faergeman Ole, Kastelein John J P, Olsson Anders G, Tikkanen Matti J, Holme Ingar, Larsen Mogens Lytken, Bendiksen Fredrik S, Lindahl Christina, Szarek Michael, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005 Nov 16;294(19):2437–2445. [PubMed]
  • Wanner Christoph, Krane Vera, März Winfried, Olschewski Manfred, Mann Johannes F E, Ruf Günther, Ritz Eberhard. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005 Jul 21;353(3):238–248. [PubMed]
  • Lee CH, de Feyter P, Serruys PW, Saia F, Lemos PA, Goedhart D, Soares PR, Umans VAWM, Ciccone M, Cortellaro M. Beneficial effects of fluvastatin following percutaneous coronary intervention in patients with unstable and stable angina: results from the Lescol intervention prevention study (LIPS). Heart. 2004 Oct;90(10):1156–1161. [PMC free article] [PubMed]
  • Holdaas H, Fellström B, Holme I, Nyberg G, Fauchald P, Jardine A, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, et al. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. J Cardiovasc Risk. 2001 Apr;8(2):63–71. [PubMed]
  • Shepherd James, Blauw Gerard J, Murphy Michael B, Bollen Edward L E M, Buckley Brendan M, Cobbe Stuart M, Ford Ian, Gaw Allan, Hyland Michael, Jukema J Wouter, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002 Nov 23;360(9346):1623–1630. [PubMed]
  • de Lemos James A, Blazing Michael A, Wiviott Stephen D, Lewis Eldrin F, Fox Keith A A, White Harvey D, Rouleau Jean-Lucien, Pedersen Terje R, Gardner Laura H, Mukherjee Robin, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004 Sep 15;292(11):1307–1316. [PubMed]
  • Birjmohun Rakesh S, Hutten Barbara A, Kastelein John J P, Stroes Erik S G. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005 Jan 18;45(2):185–197. [PubMed]
  • Robins Sander J, Rubins Hanna Bloomfield, Faas Fred H, Schaefer Ernst J, Elam Marshall B, Anderson James W, Collins Dorothea. Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care. 2003 May;26(5):1513–1517. [PubMed]
  • Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987 Nov 12;317(20):1237–1245. [PubMed]
  • Buchwald H, Varco RL, Boen JR, Williams SE, Hansen BJ, Campos CT, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, et al. Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias. Arch Intern Med. 1998 Jun 8;158(11):1253–1261. [PubMed]
  • Zhang X, Patel A, Horibe H, Wu Z, Barzi F, Rodgers A, MacMahon S, Woodward M. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol. 2003 Aug;32(4):563–572. [PubMed]
  • Crouse JR, 3rd, Byington RP, Furberg CD. HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. Atherosclerosis. 1998 May;138(1):11–24. [PubMed]
  • Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001 Apr 4;285(13):1711–1718. [PubMed]
  • Amarenco Pierre, Labreuche Julien, Lavallée Philippa, Touboul Pierre-Jean. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke. 2004 Dec;35(12):2902–2909. [PubMed]
  • MBewu AD, Durrington PN, Bulleid S, Mackness MI. The immediate effect of streptokinase on serum lipoprotein(a) concentration and the effect of myocardial infarction on serum lipoprotein(a), apolipoproteins A1 and B, lipids and C-reactive protein. Atherosclerosis. 1993 Oct;103(1):65–71. [PubMed]
  • Durrington Paul. Dyslipidaemia. Lancet. 2003 Aug 30;362(9385):717–731. [PubMed]
  • Patterson D, Slack J. Lipid abnormalities in male and female survivors of myocardial infarction and their first-degree relatives. Lancet. 1972 Feb 19;1(7747):393–399. [PubMed]
  • Marks Dalya, Wonderling David, Thorogood Margaret, Lambert Helen, Humphries Steve E, Neil H Andrew W. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ. 2002 Jun 1;324(7349):1303–1303. [PMC free article] [PubMed]
  • Sacks Frank M. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol. 2002 Jul 15;90(2):139–143. [PubMed]
  • Wierzbicki AS, Mikhailidis DP, Wray R, Schacter M, Cramb R, Simpson WG, Byrne CB. Statin-fibrate combination: therapy for hyperlipidemia: a review. Curr Med Res Opin. 2003;19(3):155–168. [PubMed]
  • Pearson Thomas A, Denke Margo A, McBride Patrick E, Battisti Wendy P, Brady William E, Palmisano Joanne. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc. 2005 May;80(5):587–595. [PubMed]
  • Ballantyne Christie M, Corsini Alberto, Davidson Michael H, Holdaas Hallvard, Jacobson Terry A, Leitersdorf Eran, März Winfried, Reckless John P D, Stein Evan A. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003 Mar 10;163(5):553–564. [PubMed]
  • Muntwyler J, Gutzwiller F. Statins and mortality. Eur Heart J. 2002 Feb;23(3):183–184. [PubMed]
  • MacMahon M, Kirkpatrick C, Cummings CE, Clayton A, Robinson PJ, Tomiak RH, Liu M, Kush D, Tobert J. A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Nutr Metab Cardiovasc Dis. 2000 Aug;10(4):195–203. [PubMed]
  • Nissen Steven E, Tuzcu E Murat, Schoenhagen Paul, Brown B Greg, Ganz Peter, Vogel Robert A, Crowe Tim, Howard Gail, Cooper Christopher J, Brodie Bruce, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004 Mar 3;291(9):1071–1080. [PubMed]
  • Grundy Scott M, Cleeman James I, Merz C Noel Bairey, Brewer H Bryan, Jr, Clark Luther T, Hunninghake Donald B, Pasternak Richard C, Smith Sidney C, Jr, Stone Neil J, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004 Jul 13;110(2):227–239. [PubMed]
  • Meigs JB, Nathan DM, Wilson PW, Cupples LA, Singer DE. Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance. The Framingham Offspring Study. Ann Intern Med. 1998 Apr 1;128(7):524–533. [PubMed]
  • Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999 Feb;22(2):233–240. [PubMed]
  • Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev. 1987 Apr;3(2):463–524. [PubMed]
  • Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998 Jul 23;339(4):229–234. [PubMed]
  • Adlerberth AM, Rosengren A, Wilhelmsen L. Diabetes and long-term risk of mortality from coronary and other causes in middle-aged Swedish men. A general population study. Diabetes Care. 1998 Apr;21(4):539–545. [PubMed]
  • Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988 Dec;37(12):1595–1607. [PubMed]
  • Liese AD, Mayer-Davis EJ, Haffner SM. Development of the multiple metabolic syndrome: an epidemiologic perspective. Epidemiol Rev. 1998;20(2):157–172. [PubMed]
  • Laaksonen David E, Lakka Hanna-Maaria, Niskanen Leo K, Kaplan George A, Salonen Jukka T, Lakka Timo A. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol. 2002 Dec 1;156(11):1070–1077. [PubMed]
  • Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984 Feb 9;310(6):356–360. [PubMed]
  • Borch-Johnsen K, Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br Med J (Clin Res Ed) 1987 Jun 27;294(6588):1651–1654. [PMC free article] [PubMed]
  • Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, Day N. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ. 2001 Jan 6;322(7277):15–18. [PMC free article] [PubMed]
  • Norhammar Anna, Tenerz Ake, Nilsson Göran, Hamsten Anders, Efendíc Suad, Rydén Lars, Malmberg Klas. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 2002 Jun 22;359(9324):2140–2144. [PubMed]
  • Davies MJ, Muehlbayer S, Garrick P, McNally PG. Potential impact of a change in the diagnostic criteria for diabetes mellitus on the prevalence of abnormal glucose tolerance in a local community at risk of diabetes: impact of new diagnostic criteria for diabetes mellitus. Diabet Med. 1999 Apr;16(4):343–346. [PubMed]
  • Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997 Apr;20(4):537–544. [PubMed]
  • Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001 May 3;344(18):1343–1350. [PubMed]
  • Knowler William C, Barrett-Connor Elizabeth, Fowler Sarah E, Hamman Richard F, Lachin John M, Walker Elizabeth A, Nathan David M. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393–403. [PMC free article] [PubMed]
  • Chiasson Jean-Louis, Josse Robert G, Gomis Ramon, Hanefeld Markolf, Karasik Avraham, Laakso Markku. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002 Jun 15;359(9323):2072–2077. [PubMed]
  • Torgerson Jarl S, Hauptman Jonathan, Boldrin Mark N, Sjöström Lars. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004 Jan;27(1):155–161. [PubMed]
  • Lindholm Lars H, Ibsen Hans, Dahlöf Björn, Devereux Richard B, Beevers Gareth, de Faire Ulf, Fyhrquist Frej, Julius Stevo, Kjeldsen Sverre E, Kristiansson Krister, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002 Mar 23;359(9311):1004–1010. [PubMed]
  • Dahlöf Björn, Sever Peter S, Poulter Neil R, Wedel Hans, Beevers D Gareth, Caulfield Mark, Collins Rory, Kjeldsen Sverre E, Kristinsson Arni, McInnes Gordon T, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005 Sep 10;366(9489):895–906. [PubMed]
  • Schrier Robert W, Estacio Raymond O, Esler Anne, Mehler Philip. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002 Mar;61(3):1086–1097. [PubMed]
  • Williams B. The unique vulnerability of diabetic subjects to hypertensive injury. J Hum Hypertens. 1999 Apr;13 (Suppl 2):S3–S28. [PubMed]
  • Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA. 1996 Dec 18;276(23):1886–1892. [PubMed]
  • Mancia Giuseppe, Grassi Guido. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens. 2002 Aug;20(8):1461–1464. [PubMed]
  • Zanchetti Alberto, Ruilope Luis M. Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens. 2002 Nov;20(11):2099–2110. [PubMed]
  • Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998 Jun 13;351(9118):1755–1762. [PubMed]
  • Zanchetti A, Hansson L, Dahlöf B, Elmfeldt D, Kjeldsen S, Kolloch R, Larochelle P, McInnes GT, Mallion JM, Ruilope L, et al. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. J Hypertens. 2001 Jun;19(6):1149–1159. [PubMed]
  • Wilmer WA, Hebert LA, Lewis EJ, Rohde RD, Whittier F, Cattran D, Levey AS, Lewis JB, Spitalewitz S, Blumenthal S, et al. Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study. Am J Kidney Dis. 1999 Aug;34(2):308–314. [PubMed]
  • Chaturvedi N, Fuller JH, Pokras F, Rottiers R, Papazoglou N, Aiello LP. Circulating plasma vascular endothelial growth factor and microvascular complications of type 1 diabetes mellitus: the influence of ACE inhibition. Diabet Med. 2001 Apr;18(4):288–294. [PubMed]
  • Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 Sep 20;345(12):851–860. [PubMed]
  • Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001 Sep 20;345(12):861–869. [PubMed]
  • Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001 Sep 20;345(12):870–878. [PubMed]
  • Tuomilehto J, Rastenyte D, Birkenhäger WH, Thijs L, Antikainen R, Bulpitt CJ, Fletcher AE, Forette F, Goldhaber A, Palatini P, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med. 1999 Mar 4;340(9):677–684. [PubMed]
  • Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA. 1996 Dec 18;276(23):1886–1892. [PubMed]
  • Pyorälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care. 1997 Apr;20(4):614–620. [PubMed]
  • Lewis SJ, Moye LA, Sacks FM, Johnstone DE, Timmis G, Mitchell J, Limacher M, Kell S, Glasser SP, Grant J, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med. 1998 Nov 1;129(9):681–689. [PubMed]
  • Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987 Nov 12;317(20):1237–1245. [PubMed]
  • Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999 Aug 5;341(6):410–418. [PubMed]
  • Sever Peter S, Dahlöf Björn, Poulter Neil R, Wedel Hans, Beevers Gareth, Caulfield Mark, Collins Rory, Kjeldsen Sverre E, Kristinsson Arni, McInnes Gordon T, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003 Apr 5;361(9364):1149–1158. [PubMed]
  • Colhoun Helen M, Betteridge D John, Durrington Paul N, Hitman Graham A, Neil H Andrew W, Livingstone Shona J, Thomason Margaret J, Mackness Michael I, Charlton-Menys Valentine, Fuller John H, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004 Aug 21;364(9435):685–696. [PubMed]
  • Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000 Aug 12;321(7258):405–412. [PMC free article] [PubMed]
  • Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995 May;28(2):103–117. [PubMed]
  • Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999 Jun 2;281(21):2005–2012. [PubMed]
  • Dormandy John A, Charbonnel Bernard, Eckland David J A, Erdmann Erland, Massi-Benedetti Massimo, Moules Ian K, Skene Allan M, Tan Meng H, Lefèbvre Pierre J, Murray Gordon D, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005 Oct 8;366(9493):1279–1289. [PubMed]
  • Malmberg K, Rydén L, Wedel H, Birkeland K, Bootsma A, Dickstein K, Efendic S, Fisher M, Hamsten A, Herlitz J, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005 Apr;26(7):650–661. [PubMed]
  • Gaede Peter, Vedel Pernille, Larsen Nicolai, Jensen Gunnar V H, Parving Hans-Henrik, Pedersen Oluf. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003 Jan 30;348(5):383–393. [PubMed]
  • Krolewski AS, Kosinski EJ, Warram JH, Leland OS, Busick EJ, Asmal AC, Rand LI, Christlieb AR, Bradley RF, Kahn CR. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol. 1987 Apr 1;59(8):750–755. [PubMed]
  • Orchard Trevor J, Olson Jon C, Erbey John R, Williams Katherine, Forrest Kimberly Y-Z, Smithline Kinder Leslie, Ellis Demetrius, Becker Dorothy J. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care. 2003 May;26(5):1374–1379. [PubMed]
  • Orchard TJ, Forrest KY, Kuller LH, Becker DJ. Lipid and blood pressure treatment goals for type 1 diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care. 2001 Jun;24(6):1053–1059. [PubMed]
  • Lee JD, Morrissey JR, Patel V. Recalculation of cardiovascular risk score as a surrogate marker of change in clinical care of diabetes patients: the Alphabet POEM project (Practice Of Evidence-based Medicine). Curr Med Res Opin. 2004 May;20(5):765–772. [PubMed]
  • Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, Walldius G. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet. 2003 Mar 1;361(9359):777–780. [PubMed]
  • Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Després JP. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Circulation. 1997 Jan 7;95(1):69–75. [PubMed]
  • Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998 May 13;279(18):1477–1482. [PubMed]
  • Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet. 1997 Aug 9;350(9075):430–436. [PubMed]
  • Danesh J, Collins R, Peto R, Lowe GD. Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Eur Heart J. 2000 Apr;21(7):515–520. [PubMed]
  • Whincup PH, Danesh J, Walker M, Lennon L, Thomson A, Appleby P, Rumley A, Lowe GDO. von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J. 2002 Nov;23(22):1764–1770. [PubMed]
  • Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Rumley A, Lowe GD. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation. 2001 May 15;103(19):2323–2327. [PubMed]
  • Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000 Oct 19;343(16):1148–1155. [PubMed]
  • Ford Earl S, Smith S Jay, Stroup Donna F, Steinberg Karen K, Mueller Patricia W, Thacker Stephen B. Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies. Int J Epidemiol. 2002 Feb;31(1):59–70. [PubMed]
  • Klerk Mariska, Verhoef Petra, Clarke Robert, Blom Henk J, Kok Frans J, Schouten Evert G. MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002 Oct 23;288(16):2023–2031. [PubMed]
  • Mackness Bharti, Durrington Paul, McElduff Patrick, Yarnell John, Azam Naheed, Watt Michael, Mackness Michael. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation. 2003 Jun 10;107(22):2775–2779. [PubMed]
  • Lohmueller Kirk E, Pearce Celeste L, Pike Malcolm, Lander Eric S, Hirschhorn Joel N. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet. 2003 Feb;33(2):177–182. [PubMed]
  • Wilson PW, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler Thromb Vasc Biol. 1996 Oct;16(10):1250–1255. [PubMed]
  • Samani NJ, Thompson JR, O'Toole L, Channer K, Woods KL. A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation. 1996 Aug 15;94(4):708–712. [PubMed]
  • Fujisawa T, Ikegami H, Kawaguchi Y, Hamada Y, Ueda H, Shintani M, Fukuda M, Ogihara T. Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia. 1998 Jan;41(1):47–53. [PubMed]
  • Boekholdt SM, Bijsterveld NR, Moons AH, Levi M, Büller HR, Peters RJ. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation. 2001 Dec 18;104(25):3063–3068. [PubMed]
  • McKeigue PM, Miller GJ, Marmot MG. Coronary heart disease in south Asians overseas: a review. J Clin Epidemiol. 1989;42(7):597–609. [PubMed]
  • Shaukat N, de Bono DP. Are Indo-origin people especially susceptible to coronary artery disease? Postgrad Med J. 1994 May;70(823):315–318. [PMC free article] [PubMed]
  • Enas EA, Yusuf S, Mehta JL. Prevalence of coronary artery disease in Asian Indians. Am J Cardiol. 1992 Oct 1;70(9):945–949. [PubMed]
  • Bhopal R. What is the risk of coronary heart disease in South Asians? A review of UK research. J Public Health Med. 2000 Sep;22(3):375–385. [PubMed]
  • Bhopal R, Unwin N, White M, Yallop J, Walker L, Alberti KG, Harland J, Patel S, Ahmad N, Turner C, et al. Heterogeneity of coronary heart disease risk factors in Indian, Pakistani, Bangladeshi, and European origin populations: cross sectional study. BMJ. 1999 Jul 24;319(7204):215–220. [PMC free article] [PubMed]
  • Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart. 2001 Mar;85(3):265–271. [PMC free article] [PubMed]
  • Ridker Paul M, Cook Nancy R, Lee I-Min, Gordon David, Gaziano J Michael, Manson Joann E, Hennekens Charles H, Buring Julie E. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005 Mar 31;352(13):1293–1304. [PubMed]
  • Freemantle N, Cleland J, Young P, Mason J, Harrison J. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999 Jun 26;318(7200):1730–1737. [PMC free article] [PubMed]
  • Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol. 1997 Jul;30(1):27–34. [PubMed]
  • Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995 May 10;273(18):1450–1456. [PubMed]
  • Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992 Sep 3;327(10):669–677. [PubMed]
  • Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995 Dec 21;333(25):1670–1676. [PubMed]
  • Teo Koon K, Yusuf Salim, Pfeffer Marc, Torp-Pedersen Christian, Kober Lars, Hall Alistair, Pogue Janice, Latini Roberto, Collins Rory. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet. 2002 Oct 5;360(9339):1037–1043. [PubMed]
  • Latini R, Maggioni AP, Flather M, Sleight P, Tognoni G. ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation. 1995 Nov 15;92(10):3132–3137. [PubMed]
  • Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000 Jan 20;342(3):145–153. [PubMed]
  • Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA. 1999 Dec 1;282(21):2058–2067. [PubMed]
  • Vogel Rolf, Indermühle Andreas, Reinhardt Jessica, Meier Pascal, Siegrist Patrick T, Namdar Mehdi, Kaufmann Philipp A, Seiler Christian. The quantification of absolute myocardial perfusion in humans by contrast echocardiography: algorithm and validation. J Am Coll Cardiol. 2005 Mar 1;45(5):754–762. [PubMed]
  • Chareonthaitawee P, Kaufmann PA, Rimoldi O, Camici PG. Heterogeneity of resting and hyperemic myocardial blood flow in healthy humans. Cardiovasc Res. 2001 Apr;50(1):151–161. [PubMed]
  • Lee CW, Park SW, Cho GY, Hong MK, Kim JJ, Kang DH, Song JK, Lee HJ, Park SJ. Pressure-derived fractional collateral blood flow: a primary determinant of left ventricular recovery after reperfused acute myocardial infarction. J Am Coll Cardiol. 2000 Mar 15;35(4):949–955. [PubMed]
  • Seiler C, Fleisch M, Garachemani A, Meier B. Coronary collateral quantitation in patients with coronary artery disease using intravascular flow velocity or pressure measurements. J Am Coll Cardiol. 1998 Nov;32(5):1272–1279. [PubMed]

Figures and Tables

Figure 1
 Joint British Societies' cardiovascular disease (CVD) risk prediction chart: non-diabetic men.
Figure 2
 Joint British Societies' CVD risk prediction chart: non-diabetic women.
Figure 3
Risk thresholds and targets for blood pressure in asymptomatic people without CVD
Figure 4
 Recommendations for combining blood pressure drugs/ABCD rule.
Figure 5
(A) Absolute reduction in LDL cholesterol (mmol/l) and absolute reduction in risk of major cardiac event (MCE). (B) Both axes are on a log scale showing relative reduction in LDL cholesterol (mmol/l) and relative reduction in risk of MCE.
Figure 6
Risk thresholds and targets for blood cholesterol in asymptomatic people without CVD. †Assessed with CVD risk chart.
Figure 7
Risk thresholds and targets for plasma blood glucose in asymptomatic people without CVD. *Impaired glucose tolerance: 2 hour glucose in an OGTT [gt-or-equal, slanted] 7.8 mmol/l and [less-than-or-eq, slant] 11.0 mmol/l. OGTT, oral glucose tolerance test. See table 13.

Articles from Heart are provided here courtesy of BMJ Group

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • PubMed
    PubMed
    PubMed citations for these articles

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...